OHR Pharmaceutical Inc.

Ohr Pharmaceutical Announces Presentation of Interim Phase II Cachexia Data

Download PDF

DOVER, DE -- (MARKET WIRE) -- 12/01/09 -- Ohr Pharmaceutical Inc. (OTCBB: OHRP), announced that interim data from the company's ongoing Phase II clinical trial of OHR/AVR118 for the treatment of Cachexia, will be presented at the 5th annual meeting of the Society on Cachexia and Wasting Disorders (SCWD), which will be held in Barcelona December 5 - December 8, 2009.

The abstract was selected for oral presentation on Monday, December 7, 2009 in the "Clinical Trials: late-breaking approaches" session.

About Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. (www.ohrpharmaceutical.com) (OTCBB: OHRP) is a biotechnology company dedicated to the development of first in class drugs for underserved therapeutic needs. Currently, Ohr is focused on the development of two drugs, OHR/AVR118 for the treatment of Cachexia and EVIZONTM for the treatment of wet-AMD.

Approval of Pharmaceutical Products

Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward looking statements are made only as the date thereof, and Ohr undertakes no obligation to update or revise the forward looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Ohr will be able to sustain operations for expected periods. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Ohr Pharmaceutical Inc.
Phone: 347-753-4389
Email: Email Contact